menu
    • menu
    [{"orgOrder":0,"company":"ObsEva","sponsor":"Scope International AG | IQVIA | Cytel | PhinC Development","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ebopiprant","moa":"prostaglandin receptor antagonists","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ObsEva \/ Scope International AG | IQVIA | Cytel | PhinC Development","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ Scope International AG | IQVIA | Cytel | PhinC Development"},{"orgOrder":0,"company":"ObsEva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ebopiprant","moa":"prostaglandin receptor antagonists","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ObsEva \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ Undisclosed"},{"orgOrder":0,"company":"ObsEva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ebopiprant","moa":"prostaglandin receptor antagonists","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ObsEva \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ Undisclosed"},{"orgOrder":0,"company":"ObsEva","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Ebopiprant","moa":"prostaglandin receptor antagonists","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":1,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"ObsEva \/ Organon","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ Organon"},{"orgOrder":0,"company":"ObsEva","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Ebopiprant","moa":"prostaglandin receptor antagonists","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"ObsEva","amount2":0.48999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.48999999999999999,"dosageForm":"Undisclosed","sponsorNew":"ObsEva \/ XOMA","highestDevelopmentStatusID":"8","companyTruncated":"ObsEva \/ XOMA"}]

    Find Clinical Drug Pipeline Developments & Deals for Ebopiprant

    Menu

    Ebopiprant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ObsEva

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ObsEva

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ebopiprant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : XOMA

                            Deal Size : $490.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon

                            Details : Under the terms of the agreement, XOMA has acquired all rights to ebopiprant held by ObsEva, including the Organon/ObsEva license agreement and the IP associated with the asset.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $15.0 million

                            November 22, 2022

                            Lead Product(s) : Ebopiprant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : XOMA

                            Deal Size : $490.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ObsEva

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ObsEva

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ebopiprant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Organon

                            Deal Size : $1,000.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022)

                            Details : Ebopiprant is an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $500.0 million

                            July 27, 2021

                            Lead Product(s) : Ebopiprant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Organon

                            Deal Size : $1,000.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ObsEva

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ObsEva

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ebopiprant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ObsEva Presents PROLONG Phase 2A Proof-of-Concept Data on Ebopiprant for the Treatment of Spontaneous Preterm ...

                            Details : Ebopiprant, when administered with atosiban infusion to women with preterm labor, reduced delivery in singleton pregnancies at 48 hours after the start of dosing by over 50% compared to atosiban alone.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 10, 2021

                            Lead Product(s) : Ebopiprant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ObsEva

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ObsEva

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ebopiprant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant for Treatment o...

                            Details : In the PROLONG study, ebopiprant reduced delivery in singleton pregnancies at 48 hours after the start of dosing by 55% compared to atosiban alone. Overall, 12.5% of women receiving ebopiprant delivered within 48 hours of starting treatment compared to p...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 16, 2020

                            Lead Product(s) : Ebopiprant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ObsEva

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ObsEva

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ebopiprant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Scope International AG | IQVIA | Cytel | PhinC Development

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PoC Study of OBE022 in Threatened Preterm Labour

                            Details : OBE022 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obstetric Labor, Premature.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 11, 2017

                            Lead Product(s) : Ebopiprant

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Scope International AG | IQVIA | Cytel | PhinC Development

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth